Skip to main content

Merilog FDA Approval History

Last updated by Judith Stewart, BPharm on July 15, 2025.

FDA Approved: Yes (First approved February 14, 2025)
Brand name: Merilog
Generic name: insulin aspart-szjj
Dosage form: Injection
Company: Sanofi
Treatment for: Diabetes Mellitus

Merilog (insulin aspart-szjj) is a rapid acting human insulin analog biosimilar to NovoLog (insulin aspart) indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

NovoLog Biosimilars

Brand Name Generic Name Date of Approval
Merilog insulin aspart-szjj February 14, 2025
Kirsty insulin aspart-xjhz July 15, 2025

Development timeline for Merilog

DateArticle
Feb 16, 2025Approval FDA Approves Merilog (insulin-aspart-szjj), a Biosimilar to NovoLog

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.